Molnupiravir, Bamlanivimab, Remdesivir, and Ivermectin Studies

Molnupiravir, Bamlanivimab, Remdesivir, and Ivermectin Studies If authorized/approved, Merck's Molnupiravir is an excellent new addition to the toolset for the physicians to manage COVID-19. I believe this will be the last straw for the SARS-COV-2 to become an endemic from a pandemic. Let's review the timeline, trial, order placement, and possibly imminent EUA as compared to other drugs like Bamlanivimab, etc. Buy me a coffee :-) https://www.buymeacoffee.com/DrMobeenSyed Become my patron: https://www.patreon.com/mobeensyed?fan_landing=true Looking to support my educational work? Donate here: https://paypal.me/mobeensyed?locale.x=en_US Molnupiravir information and the study that is the basis for its possible EUA. https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ https://www.drugs.com/history/molnupiravir.html https://clinicaltrials.gov/ct2/show/study/NCT04575597?term=molnupiravir&draw=2&rank=2 https://en.wikipedia.org/wiki/Molnupiravir https://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277160/ Some studies for other drugs https://ivmmeta.com/#fig_fpr https://journals.sagepub.com/doi/10.1177/03000605211013550 https://clinicaltrials.gov/ProvidedDocs/31/NCT04523831/Prot_ICF_000.pdf https://pubmed.ncbi.nlm.nih.gov/20946067/ https://pubmed.ncbi.nlm.nih.gov/32251768/ WHO study showing no benefit of Remdesivir https://www.bmj.com/content/371/bmj.m4057 Another analysis finds ambiguous or no effect of Remdesivir https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255093 A good message from Dr. Eric Osgood in response to an analysis of a drug: https://mobile.twitter.com/gidmk/status/1412635825771192320 Bamlanivimab trial: https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis References in the order I displayed: https://mobile.twitter.com/gidmk/status/1412635825771192320 https://pubmed.ncbi.nlm.nih.gov/20946067/ https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 https://jamanetwork.com/journals/jama/fullarticle/2775647 https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html?s_cid=11609:vaccine%20efficacy%20against%20delta%20variant:sem.ga:p:RG:GM:gen:PTN.Grants:FY22 https://www.medrxiv.org/content/10.1101/2021.06.28.21259420v3 https://clinicaltrials.gov/ct2/show/study/NCT04575597?term=molnupiravir&draw=2&rank=2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277160/ https://en.wikipedia.org/wiki/Molnupiravir https://www.drugs.com/history/molnupiravir.html https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ https://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf https://ivmmeta.com/#fig_fpr https://pubmed.ncbi.nlm.nih.gov/32251768/ https://journals.sagepub.com/doi/10.1177/03000605211013550 https://clinicaltrials.gov/ProvidedDocs/31/NCT04523831/Prot_ICF_000.pdf https://www.bmj.com/content/371/bmj.m4057 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255093 Disclaimer: This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only. Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional. #drbeen #koolbeens #COVID